|
1
|
Muratovska A, Zhou C, He S, Goodyer P and
Eccles MR: Paired-Box genes are frequently expressed in cancer and
often required for cancer cell survival. Oncogene. 22:7989–7997.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siehl JM, Thiel E, Heufelder K, et al:
Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the
paired box genes PAX2 and PAX8 and by the haematopoietic
transcription factor GATA-1 in human acute myeloid leukaemias. Br J
Haematol. 123:235–242. 2003.
|
|
3
|
Nonaka D, Chiriboga L and Soslow RA:
Expression of pax8 as a useful marker in distinguishing ovarian
carcinomas from mammary carcinomas. Am J Surg Pathol. 32:1566–1571.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poleev A, Wendler F, Fickenscher H, et al:
Distinct functional properties of three human paired-box-protein,
PAX8, isoforms generated by alternative splicing in thyroid, kidney
and Wilms’ tumors. Eur J Biochem. 228:899–911. 1995.PubMed/NCBI
|
|
5
|
Mittag J, Winterhager E, Bauer K and
Grummer R: Congenital hypothyroid female pax8-deficient mice are
infertile despite thyroid hormone replacement therapy.
Endocrinology. 148:719–725. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Macchia PE, Lapi P, Krude H, et al: PAX8
mutations associated with congenital hypothyroidism caused by
thyroid dysgenesis. Nat Genet. 19:83–86. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dehbi M and Pelletier J: PAX8-mediated
activation of the wt1 tumor suppressor gene. Embo J. 15:4297–4306.
1996.PubMed/NCBI
|
|
8
|
Haynes CM, Sangoi AR and Pai RK: PAX8 is
expressed in pancreatic well-differentiated neuroendocrine tumors
and in extrapancreatic poorly differentiated neuroendocrine
carcinomas in fine-needle aspiration biopsy specimens. Cancer
Cytopathol. 119:193–201. 2011. View Article : Google Scholar
|
|
9
|
Knoepp SM, Kunju LP and Roh MH: Utility of
PAX8 and PAX2 immunohistochemistry in the identification of renal
cell carcinoma in diagnostic cytology. Diagn Cytopathol.
40:667–672. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marques AR, Espadinha C, Catarino AL, et
al: Expression of PAX8-PPAR gamma 1 rearrangements in both
follicular thyroid carcinomas and adenomas. J Clin Endocrinol
Metab. 87:3947–3952. 2002.PubMed/NCBI
|
|
11
|
Nikiforov YE: Molecular diagnostics of
thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
|
|
12
|
Tong GX, Devaraj K, Hamele-Bena D, et al:
PAX8: A marker for carcinoma of Müllerian origin in serous
effusions. Diagn Cytopathol. 39:562–566. 2011.
|
|
13
|
Nikiforova MN, Lynch RA, Biddinger PW, et
al: RAS point mutations and PAX8-PPAR gamma rearrangement in
thyroid tumors: evidence for distinct molecular pathways in thyroid
follicular carcinoma. J Clin Endocrinol Metab. 88:2318–2326. 2003.
View Article : Google Scholar
|
|
14
|
Nonaka D, Tang Y, Chiriboga L, Rivera M
and Ghossein R: Diagnostic utility of thyroid transcription factors
Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol.
21:192–200. 2008.PubMed/NCBI
|
|
15
|
Tacha D, Zhou D and Cheng L: Expression of
PAX8 in normal and neoplastic tissues: a comprehensive
immunohistochemical study. Appl Immunohistochem Mol Morphol.
19:293–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kroll TG, Sarraf P, Pecciarini L, et al:
PAX8-PPARgamma 1 fusion in oncogene human thyroid carcinoma.
Science. 289:1357–1360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nikiforova MN, Biddinger PW, Caudill CM,
Kroll TG and Nikiforov YE: PAX8-PPARgamma rearrangement in thyroid
tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol.
26:1016–1023. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cazzaniga G, Daniotti M, Tosi S, et al:
The paired box domain gene PAX5 is fused to ETV6/TEL in an acute
lymphoblastic leukemia case. Cancer Res. 61:4666–4670.
2001.PubMed/NCBI
|
|
19
|
Ozcan A, Shen SS, Hamilton C, et al: PAX 8
expression in non-neoplastic tissues, primary tumors and metastatic
tumors: a comprehensive immunohistochemical study. Mod Pathol.
24:751–764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albadine R, Schultz L, Illei P, et al:
PAX8 (+)/p63 (−) immunostaining pattern in renal collecting duct
carcinoma (CDC): a useful immunoprofile in the differential
diagnosis of CDC versus urothelial carcinoma of upper urinary
tract. Am J Surg Pathol. 34:965–969. 2010.
|
|
21
|
Long KB, Srivastava A, Hirsch MS and
Hornick JL: PAX8 expression in well-differentiated pancreatic
endocrine tumors: correlation with clinicopathologic features and
comparison with gastrointestinal and pulmonary carcinoid tumors. Am
J Surg Pathol. 34:723–729. 2010.PubMed/NCBI
|
|
22
|
Sangoi AR, Ohgami RS and Pai RK, Beck AH,
McKenney JK and Pai RK: PAX8 expression reliably distinguishes
pancreatic well-differentiated neuroendocrine tumors from ileal and
pulmonary well-differentiated neuroendocrine tumors and pancreatic
acinar cell carcinoma. Mod Pathol. 24:412–424. 2011. View Article : Google Scholar
|
|
23
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagele F, Petru E, Medl M, Kainz C, Graf
AH and Sevelda P: Preoperative CA 125: an independent prognostic
factor in patients with stage I epithelial ovarian cancer. Obstet
Gynecol. 86:259–264. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eltabbakh GH, Yadav PR and Morgan A:
Clinical picture of women with early stage ovarian cancer. Gynecol
Oncol. 75:476–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schaner ME, Ross DT, Ciaravino G, et al:
Gene expression patterns in ovarian carcinomas. Mol Biol Cell.
14:4376–4386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bowen NJ, Logani S, Dickerson EB, et al:
Emerging roles for PAX8 in ovarian cancer and endosalpingeal
development. Gynecol Oncol. 104:331–337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Laury AR, Hornick JL, Perets R, et al:
PAX8 reliably distinguishes ovarian serous tumors from malignant
mesothelioma. Am J Surg Pathol. 34:627–635. 2010.PubMed/NCBI
|
|
29
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Handbook. 7th edition.
Springer; New York, NY: 2010
|
|
30
|
Shivakumarswamy U, Arakeri SU, Karigowdar
MH and Yelikar B: Diagnostic utility of the cell block method
versus the conventional smear study in pleural fluid cytology. J
Cytol. 29:11–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bárcena C and Oliva E: WT1 expression in
the female genital tract. Adv Anat Pathol. 18:454–465. 2011.
|
|
32
|
McKnight R, Cohen C and Siddiqui MT:
Utility of paired box gene 8 (PAX8) expression in fluid and
fine-needle aspiration cytology: an immunohistochemical study of
metastatic ovarian serous carcinoma. Cancer Cytopathol.
118:298–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiang L, Zheng W and Kong B: Detection of
PAX8 and p53 is beneficial in recognizing metastatic carcinomas in
pelvic washings, especially in cases with suspicious cytology.
Gynecol Oncol. 127:595–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Landen CN, Birrer MJ and Sood AK: Early
events in the pathogenesis of epithelial ovarian cancer. J Clin
Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Auersperg N, Wong AST, Choi KC, Kang SK
and Leung PCK: Ovarian surface epithelium: biology, endocrinology
and pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
|
|
36
|
Medeiros F, Muto MG, Lee Y, et al: The
tubal fimbria is a preferred site for early adenocarcinoma in women
with familial ovarian cancer syndrome. Am J Surg Pathol.
30:230–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Callahan MJ, Crum CP, Medeiros F, et al:
Primary fallopian tube malignancies in BRCA-positive women
undergoing surgery for ovarian cancer risk reduction. J Clin Oncol.
25:3985–3990. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carcangiu ML, Radice P, Manoukian S, et
al: Atypical epithelial proliferation in fallopian tubes in
prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2
germline mutation carriers. Int J Gynecol Pathol. 23:35–40. 2004.
View Article : Google Scholar
|
|
39
|
Finch A, Shaw P, Rosen B, Murphy J, Narod
SA and Colgan TJ: Clinical and pathologic findings of prophylactic
salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol
Oncol. 100:58–64. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Abushahin N, Pang S, et al: Tubal
origin of ‘ovarian’ low-grade serous carcinoma. Mod Pathol.
24:1488–1499. 2011.
|
|
41
|
Marquez RT, Baggerly KA, Patterson AP, et
al: Patterns of gene expression in different histotypes of
epithelial ovarian cancer correlate with those in normal fallopian
tube, endometrium and colon. Clin Cancer Res. 11:6116–6126. 2005.
View Article : Google Scholar : PubMed/NCBI
|
